scholarly journals Cyclophosphamide combined with mitoxantrone and cytarabine is an effective salvage regimen for patients with acute myeloid leukemia who experienced primary induction failure or relapse

2015 ◽  
Vol 4 (2) ◽  
pp. 285-289 ◽  
Author(s):  
SHUNING WEI ◽  
YINGCHANG MI ◽  
HUI WEI ◽  
DONG LIN ◽  
KANQI LIU ◽  
...  
Keyword(s):  
Acute Myeloid Leukemia ◽  
Myeloid Leukemia ◽  
Salvage Regimen ◽  
Primary Induction ◽  
Induction Failure ◽  
Acute Myeloid

scholarly journals NUP-98 Rearrangements Led to the Identification of Candidate Biomarkers for Primary Induction Failure in Pediatric Acute Myeloid Leukemia

2021 ◽  
Vol 22 (9) ◽  
pp. 4575
Author(s):  
Vincenza Barresi ◽  
Virginia Di Bella ◽  
Nellina Andriano ◽  
Anna Provvidenza Privitera ◽  
Paola Bonaccorso ◽  
...  
Keyword(s):  
Acute Myeloid Leukemia ◽  
Myeloid Leukemia ◽  
Mutational Analysis ◽  
Integrated Analysis ◽  
Induction Phase ◽  
Pediatric Acute Myeloid Leukemia ◽  
Expression Arrays ◽  
Primary Induction ◽  
Induction Failure ◽  
Acute Myeloid

Conventional chemotherapy for acute myeloid leukemia regimens generally encompass an intensive induction phase, in order to achieve a morphological remission in terms of bone marrow blasts (<5%). The majority of cases are classified as Primary Induction Response (PIR); unfortunately, 15% of children do not achieve remission and are defined Primary Induction Failure (PIF). This study aims to characterize the gene expression profile of PIF in children with Acute Myeloid Leukemia (AML), in order to detect molecular pathways dysfunctions and identify potential biomarkers. Given that NUP98-rearrangements are enriched in PIF-AML patients, we investigated the association of NUP98-driven genes in primary chemoresistance. Therefore, 85 expression arrays, deposited on GEO database, and 358 RNAseq AML samples, from TARGET program, were analyzed for “Differentially Expressed Genes” (DEGs) between NUP98+ and NUP98-, identifying 110 highly confident NUP98/PIF-associated DEGs. We confirmed, by qRT-PCR, the overexpression of nine DEGs, selected on the bases of the diagnostic accuracy, in a local cohort of PIF patients: SPINK2, TMA7, SPCS2, CDCP1, CAPZA1, FGFR1OP2, MAN1A2, NT5C3A and SRP54. In conclusion, the integrated analysis of NUP98 mutational analysis and transcriptome profiles allowed the identification of novel putative biomarkers for the prediction of PIF in AML.

scholarly journals Decitabine as salvage therapy for primary induction failure of acute myeloid leukemia

2017 ◽  
Vol 56 (8) ◽  
pp. 1120-1121 ◽  
Author(s):  
Pasquale Niscola ◽  
Benedetta Neri ◽  
Gianfranco Catalano ◽  
Luciana Morino ◽  
Marco Giovannini ◽  
...  
Keyword(s):  
Acute Myeloid Leukemia ◽  
Salvage Therapy ◽  
Myeloid Leukemia ◽  
Primary Induction ◽  
Induction Failure ◽  
Acute Myeloid

Mitoxantrone and etoposide with or without intermediate dose cytarabine for the treatment of primary induction failure or relapsed acute myeloid leukemia

2012 ◽  
Vol 36 (4) ◽  
pp. 394-396 ◽  
Author(s):  
Steven M. Trifilio ◽  
Alfred W. Rademaker ◽  
Diane Newman ◽  
Katherine Coyle ◽  
Katrin Carlson-Leuer ◽  
...  
Keyword(s):  
Acute Myeloid Leukemia ◽  
Myeloid Leukemia ◽  
Primary Induction ◽  
Induction Failure ◽  
Relapsed Acute Myeloid Leukemia ◽  
Acute Myeloid ◽  
Intermediate Dose

scholarly journals Fate of Patients with Newly Diagnosed Acute Myeloid Leukemia Who Fail Primary Induction Therapy

2015 ◽  
Vol 21 (3) ◽  
pp. 559-564 ◽  
Author(s):  
Megan Othus ◽  
Frederick R. Appelbaum ◽  
Stephen H. Petersdorf ◽  
Kenneth J. Kopecky ◽  
Marilyn Slovak ◽  
...  
Keyword(s):  
Acute Myeloid Leukemia ◽  
Induction Therapy ◽  
Myeloid Leukemia ◽  
Newly Diagnosed ◽  
Primary Induction ◽  
Acute Myeloid

scholarly journals Deciphering the Therapeutic Resistance in Acute Myeloid Leukemia

2020 ◽  
Vol 21 (22) ◽  
pp. 8505
Author(s):  
Carmelo Gurnari ◽  
Simona Pagliuca ◽  
Valeria Visconte
Keyword(s):  
Acute Myeloid Leukemia ◽  
Complete Remission ◽  
Myeloid Leukemia ◽  
Cellular Differentiation ◽  
Therapeutic Response ◽  
Chemotherapeutic Agents ◽  
Therapeutic Resistance ◽  
Hypomethylating Agents ◽  
Induction Failure ◽  
Acute Myeloid

Acute myeloid leukemia (AML) is a clonal hematopoietic disorder characterized by abnormal proliferation, lack of cellular differentiation, and infiltration of bone marrow, peripheral blood, or other organs. Induction failure and in general resistance to chemotherapeutic agents represent a hindrance for improving survival outcomes in AML. Here, we review the latest insights in AML biology concerning refractoriness to therapies with a specific focus on cytarabine and daunorubicin which still represent milestones agents for inducing therapeutic response and disease eradication. However, failure to achieve complete remission in AML is still high especially in elderly patients (40–60% in patients >65 years old). Several lines of basic and clinical research have been employed to improve the achievement of complete remission. These lines of research include molecular targeted therapy and more recently immunotherapy. In terms of molecular targeted therapies, specific attention is given to DNMT3A and TP53 mutant AML by reviewing the mechanisms underlying epigenetic therapies’ (e.g., hypomethylating agents) resistance and providing critical points and hints for possible future therapies overcoming AML refractoriness.

Impact of salvage regimens on response and overall survival in acute myeloid leukemia with induction failure

Leukemia ◽  
2017 ◽  
Vol 31 (6) ◽  
pp. 1306-1313 ◽  
Author(s):  
M Wattad ◽  
◽  
D Weber ◽  
K Döhner ◽  
J Krauter ◽  
...  
Keyword(s):  
Overall Survival ◽  
Acute Myeloid Leukemia ◽  
Myeloid Leukemia ◽  
Induction Failure ◽  
Acute Myeloid
Sign in / Sign up

Export Citation Format

Share Document